Adamas Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference
November 17 2015 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that
Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of
Adamas, will present at the Piper Jaffray Healthcare Conference in
New York on Wednesday, December 2, 2015 at 8:30 a.m. Eastern Time.
The presentation will be webcast live from the investor
relations section of the Adamas website at
http://ir.adamaspharma.com/events.cfm and available for replay
until January 2, 2016.
About Adamas PharmaceuticalsAdamas
Pharmaceuticals, Inc. is driven to improve the lives of those
affected by chronic disorders of the central nervous system.
The company seeks to achieve this by modifying the pharmacokinetic
profiles of approved drugs to create novel therapeutics for use
alone and in fixed-dose combination products. Adamas is currently
developing ADS-5102, its lead wholly-owned product candidate, for
the treatment of levodopa-induced dyskinesia (LID) associated with
Parkinson's disease and for the treatment of major symptoms
associated with multiple sclerosis in patients with walking
impairment. The company's portfolio also includes Namzaric™ and
Namenda XR®, two approved products with Forest Laboratories
Holdings Limited, an indirect wholly-owned subsidiary of Allergan
plc. Forest is responsible for marketing both products in the
United States under an exclusive license from Adamas. For more
information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co.
KGaA.
For questions, please contact:
Susan Lehner
Investor Relations & Corporate Communications
Adamas Pharmaceuticals, Inc.
Phone: 510-450-3567
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024